Motor and nonmotor complications in Parkinson's disease: An argument for continuous drug delivery?

Journal of Neural Transmission

Volumn 120, Issue 9, 2013, Pages 1305-1320

  Chaudhuri, K Ray ^a   Rizos, Alexandra ^a   Sethi, Kapil D ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Continuous drug delivery; Motor complications; Nonmotor fluctuations; Parkinson's disease

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); APOMORPHINE; BENSERAZIDE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE;

AREA UNDER THE CURVE; AROUSAL; ARTICLE; ATTENTION; BASAL GANGLION; BECK DEPRESSION INVENTORY; BLOOD BRAIN BARRIER; BRAIN DEPTH STIMULATION; CLINICAL PRACTICE; COGNITION; DIZZINESS; DOPAMINERGIC NERVE CELL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DYSKINESIA; DYSTONIA; EUROPEAN UNION; FOLLOW UP; GAMBLING; HALLUCINATION; HOMEOSTASIS; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; IN VIVO STUDY; INVOLUNTARY MOVEMENT; LIVER FUNCTION; LIVER TOXICITY; LONG TERM CARE; MATRIX TABLET; MEMORY; META ANALYSIS; MONOTHERAPY; MOTOR PERFORMANCE; NASOGASTRIC TUBE; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIST; NOCTURIA; ON OFF PHENOMENON; OPEN STUDY; OSCILLATION; PAIN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PLASMA HALF LIFE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SEROTONINERGIC SYSTEM; SHOPPING; SKIN NODULE; SLOW RELEASE FORMULATION; SOMNOLENCE; STEADY STATE; STOMACH EMPTYING; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SUSTAINED DRUG RELEASE; SYNAPTOSOME; TRANSDERMAL PATCH; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL ANALOG SCALE;

ANTIPARKINSON AGENTS; DELAYED-ACTION PREPARATIONS; DOPAMINE AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MOVEMENT DISORDERS; PARKINSON DISEASE;

EID: 84883455518     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-0981-5     Document Type: Article

References (132)

1. Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 6:826-829
2. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L et al (2007) Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 22:1145-1149
3. Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L et al (2008) Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 5:244-246
4. Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P (2010a) Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. CNS Drugs 24:119-129
5. Antonini A, Bondiolotti G, Natuzzi F, Bareggi SR (2010b) Levodopa and 3-OMD levels in Parkinson patients treated with duodena. Eur Neuropsychopharmacol 20:683-687
6. ® (2012) Apomorphine hydrochloride injection (package insert). Ravensburg, Germany: Vetter Pharma-Fertigung GmbH & Co. KG; Brisbane, CA: Tercica, Inc., a subsidiary of Ipsen Group, Feb 2012
7. ® (2009) Rasagiline mesylate tablets (package insert). Kansas City, MO: Teva Neuroscience, Inc., Dec 2009
8. Baker WL, Silver D, White CM, Kluger J, Aberle J, Patel AA, Coleman CI (2009) Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord 15:287-294
9. Bibbiani F, Costantini LC, Patel R, Chase TN (2005) Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 192:73-78
10. Braun M, Cawello W, Boekens H, Horstmann R (2009) Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol 67:209-215
11. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN (1994) Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 36:27-31
12. Brooks DJ, Papapetropoulos S, Vandenhende F, Tomic D, He P, Coppell A, O'Neill G (2010) An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clin Neuropharmacol 33:55-60
13. Cawello W, Wolff HM, Meuling WJ, Horstmann R, Braun M (2007) Transdermal administration of radiolabelled (14C) rotigotine by a patch formulation: a mass balance trial. Clin Pharmacokinet 46:851-857
14. Cawello W, Braun M, Boekens H (2009) Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 37:2055-2060
15. Cedarbaum JM (1987) Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 13:141-178
16. Cedarbaum JM, Kutt H, McDowell FH (1989) A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 39(11 Suppl 2):38-44
17. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F (2005) Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 20:224-230
18. Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM (1989) Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 39(11 Suppl 2):7-10
19. Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464-474
20. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Pavo B, Tluk S et al (2010) The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 25:704-709
21. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P (2011) Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 17:717-723
22. Colzi A, Turner K, Lees AJ (1998) Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 64:573-576
23. Damiano AM, McGrath MM, Willian MK, Snyder CF, LeWitt PA, Reyes PF et al (2000) Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res 9:87-100
24. Deleu D, Northway MG, Hanssens Y (2002) Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 41:261-309
25. Deleu D, Hanssens Y, Northway MG (2004) Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 21:687-709
26. Dempski RE, Scholtz EC, Oberholtzer ER, Yeh KC (1989) Pharmaceutical design and development of a Sinemet controlled-release formulation. Neurology 39(11 Suppl 2):20-24
27. Di Giovanni G, Di Matteo V, Pierucci M, Esposito E (2008) Serotonin-dopamine interaction: electrophysiological evidence. Prog Brain Res 172:45-71
28. Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R et al (2008) Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 31:151-166
29. ® (2011) Selegiline hydrochloride (package insert). Morgantown, WV: Somerset Pharmaceuticals, Inc., Aug 2011
30. Erni W, Held K (1987) The hydrodynamically balanced system: a novel principle of controlled drug release. Eur Neurol 27(Suppl 1):21-27
31. Fahn S, Elton RL, UPDRS Development Committee (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease. Macmillan, Florham Park, pp 153-163
32. Frankel JP, Kempster PA, Bovingdon M, Webster R, Lees AJ, Stern GM (1989) The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 52:1063-1067
33. Fung VS, Herawati L, Wan Y, Movement Disorder Society of Australia Clinical Research and Trials Group, QUEST-AP Study Group (2009) Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Mov Disord 24:25-31
34. Gancher ST, Woodward WR, Boucher B, Nutt JG (1989) Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 26:232-238
35. García-Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro García A, Alonso Frech F, Alvarez López M et al (2008) Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 23:1130-1136
36. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH, SP513 Investigators (2007) Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22:2398-2404
37. Goto Y, Otani S, Grace AA (2007) The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 53:583-587
38. Grace AA (2008) Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. Mov Disord 23(Suppl 3):S560-S569
39. Grandas F, Galiano ML, Tabernero C (1999) Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 246:1127-1133
40. Gunal DI, Nurichalichi K, Tuncer N, Bekiroglu N, Aktan S (2002) The clinical profile of nonmotor fluctuations in Parkinson's disease patients. Can J Neurol Sci 29:61-64
41. Hauser RA (2012) IPX066: a novel carbidopa-levodopa extended-release formulation. Expert Rev Neurother 12:133-140
42. Hauser RA, Lew MF, Hurtig HI, Wojcieszek J, Fitzer-Attas CJ, TEMPO Open-label Study Group (2009a) Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 24:564-573
43. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A, FIRST-STEP Study Group (2009b) Double-blind trial of levodopa/carbidopa/ entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 24:541-550
44. Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L et al (2010) Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 25:2542-2549
45. Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (2006) Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 29:80-86
46. Hofstee DJ, Neef C, van Laar T, Jansen EN (1994) Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses. Clin Neuropharmacol 17:45-52
47. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T et al (2009) Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468-1474
48. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, European Federation of Neurological Societies, Movement Disorder Society-European Section et al (2006) Review of the therapeutic management of Parkinson's disease: report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section: part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 13:1170-1185
49. Isacson D, Bingefors K, Kristiansen IS, Nyholm D (2008) Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand 118:379-386
50. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997a) The Parkinson's disease questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 26:353-357
51. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997b) The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. Psychol Health 12:805-814
52. Jenner P (2008) Preventing and controlling dyskinesia in Parkinson's disease - a view of current knowledge and future opportunities. Mov Disord 23(Suppl 3):S585-S598
53. Jenner P (2009) From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism Relat Disord 15(Suppl 4):S18-S23
54. Jenner P, Könen-Bergmann M, Schepers C, Haertter S (2009) Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther 31:2698-2711
55. Kaakkola S, Männistö PT, Nissinen E, Vuorela A, Mäntylä R (1985) The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurol Scand 72:385-391
56. Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L et al (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 20:151-157
57. Kieburtz K, Antonini A, Olanow CW, Fernandez HH, Espay AJ, Standaert DG, Hass S (2012) Randomized, phase 3, double-blind, double-dummy study of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease: functional and quality-of-life outcomes (abstract). Mov Disord 27(Suppl 1):385
58. Klostermann F, Jugel C, Müller T, Marzinzik F (2012) Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 119:369-372
59. Kulisevsky J, Pascual-Sedano B, Barbanoj M, Gironell A, Pagonabarraga J, García-Sánchez C (2007) Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: a double-blind study. Mov Disord 22:62-67
60. Kurlan R, Rothfield KP, Woodward WR, Nutt JG, Miller C, Lichter D, Shoulson I (1988) Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology 38:419-421
61. Kvernmo T, Härtter S, Burger E (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28:1065-1078
62. LeWitt PA (2004) Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 62(6 Suppl 4):S8-S11
63. LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 68:1262-1267
64. LeWitt PA, Jennings D, Lyons KE, Pahwa R, Rabinowicz AL, Wang J et al (2009) Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. Mov Disord 24:1319-1324
65. Manson AJ, Hanagasi H, Turner K, Patsalos PN, Carey P, Ratnaraj N, Lees AJ (2001) Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 124:331-340
66. Markham C, Diamond SG, Treciokas LJ (1974) Carbidopa in Parkinson disease and in nausea and vomiting of levodopa. Arch Neurol 31:128-133
67. Marsden CD (1982) The mysterious motor function of the basal ganglia: the Robert Wartenberg lecture. Neurology 32:514-539
68. Marsden CD, Parkes JD (1976) "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1:292-296
69. Martinez-Martin P, Rodriguez-Blazquez C, Abe K, Bhattacharyya KB, Bloem BR, Carod-Artal FJ et al (2009) International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 73:1584-1591
70. Martinez-Martin P, Todorova A, Odin P, Odin T, Henriksen Y, Naidu S et al (2010) Motor and non motor efficacy of subcutaneous apomorphine infusion in advanced PD compared to Parkinson's patients on conventional therapy (MDS abstract 711). Mov Disord 25(7 Suppl 2):S421
71. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, NMSS Validation Group (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 26:399-406
72. Martínez-Martín P, Benito-León J, Burguera JA, Castro A, Linazasoro G, Martínez-Castrillo JC et al (2005) The SCOPA-motor scale for assessment of Parkinson's disease is a consistent and valid measure. J Clin Epidemiol 58:674-679
73. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A (1994) Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57:186-189
74. Nicolle E, Pollak P, Serre-Debeauvais F, Richard P, Gervason CL, Broussolle E, Gavend M (1993) Pharmacokinetics of apomorphine in parkinsonian patients. Fundam Clin Pharmacol 7:245-252
75. Nilsson D, Nyholm D, Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurol Scand 104:343-348
76. Nutt JG (1996) Effects of catechol-O-methyl transferase (COMT) inhibition on the pharmacokinetics of l-dopa. Adv Neurol 69:493-496
77. Nutt JG (2000) Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 55(11 Suppl 4):S33-S37
78. Nutt JG, Gancher ST, Woodward WR (1989) Motor fluctuations in Parkinson's disease. Ann Neurol 25:633-634
79. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH et al (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44:913-919
80. Nutt JG, Obeso JA, Stocchi F (2000) Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 23(10 Suppl):S109-S115
81. Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernäs H, Nyström C, Aquilonius SM (2003) Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 26:156-163
82. Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R et al (2005) Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson disease. Neurology 64:216-223
83. Obeso JA, Olanow CW, Nutt JG (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci 23(Suppl):S2-S7
84. Obeso JA, Marin C, Rodriguez-Oroz MC, Blesa J, Benitez-Temiño B, Mena-Segovia J et al (2008) The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol 64(Suppl 2):S30-S46
85. Olanow CW, Obeso JA (2000) Preventing levodopa-induced dyskinesia. Ann Neurol 47:167-178
86. Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5:677-687
87. Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson disease. Neurology 72(21 Suppl 4):S1-S136
88. Olanow CW, Chatamra K, Benesh J, Pritchett YL, Lenz RA (2011) Design of a randomized, double-blind, double-dummy, placebo-controlled study of levodopa-carbidopa intestinal gel in patients currently receiving optimized treatment for advanced Parkinson's disease. Mov Disord 26(Suppl 2):S137
89. Olanow CW, Antonini A, Kieburtz K, Fernandez HH, Espay AJ, Standaert DG, Vanagunas AD (2012) Randomized, double-blind, double-dummy study of continuous infusion of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease: efficacy and safety (abstract). Mov Disord 27(Suppl 1):411
90. Pahwa R, Lyons K, McGuire D, Silverstein P, Zwiebel F, Robischon M, Koller WC (1997) Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Mov Disord 12:677-681
91. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H et al (2006) Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:983-995
92. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, EASE-PD Adjunct Study Investigators et al (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68:1108-1115
93. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early parkinson disease. Arch Neurol 61:561-566
94. Parkinson Study Group CALM Cohort Investigators (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 66:563-570
95. Pearce RK, Banerji T, Jenner P, Marsden CD (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-dopa in the MPTP-treated marmoset. Mov Disord 13:234-241
96. Pfieffer RF (2005) A promising new technology for Parkinson's disease. Neurology 65(Suppl 1):S6-S10
97. Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A (2000) The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 68:589-594
98. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, SP 515 Investigators (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6:513-520
99. Politis M, Piccini P, Pavese N, Koh SB, Brooks DJ (2008) Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp Neurol 214:112-116
100. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, LARGO study group (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with Rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947-954
101. Reuter I, Ellis CM, Chaudhuri KR (1999) Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 100:163-167
102. Rizos A, Martinez-Martin P, Martin A, Henriksen T, Kessel B, Koch I, Durner G (2012) European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD (abstract). Mov Disord 27(Suppl 1):161
103. Robertson DR, Wood ND, Everest H, Monks K, Waller DG, Renwick AG, George CF (1989) The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 28:61-69
104. Ruottinen HM, Rinne UK (1996a) Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 19:222-233
105. Ruottinen HM, Rinne UK (1996b) Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 60:36-40
106. Sage JI, Mark MH (1994) Pharmacokinetics of continuous-release carbidopa/levodopa. Clin Neuropharmacol 17(Suppl 2):S1-S6
107. Schapira AHV, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M et al (2011) Extended-release pramipexole in advanced Parkinson's disease: a randomized controlled trial. Neurology 77:767-774
108. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H (2009) The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 379:73-86
109. Schultz W (1994) Behavior-related activity of primate dopamine neurons. Rev Neurol (Paris) 150:634-639
110. Simuni T, Sethi K (2008) Nonmotor manifestations of Parkinson's disease. Ann Neurol 64(Suppl 2):S65-S80
111. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease-PD Monotherapy Study Investigators (2008) Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 24:2883-2895
112. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E et al (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18-27
113. Stocchi F, Giorgi L, Hunter B, Schapira AH (2011) PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Mov Disord 26:1259-1265
114. Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ et al (2008) Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2:CD006564
115. Stowe R, Ives N, Clarke CE, van Hilten J, Wheatley K et al (2010) Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database Syst Rev 7:CD007166
116. Talati R, Reinhart K, Baker W, White CM, Coleman CI (2009) Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord 15:500-505
117. ® (2009) Tolcapone (package insert). Aliso Viejo, CA: Valeant Pharmaceuticals North America, June 2009
118. Tolosa E, Martí MJ, Valldeoriola F, Molinuevo JL (1998) History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 50(6 Suppl 6):S2-S10
119. Tompson DJ, Vearer D (2007) Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease. Clin Ther 29:2654-2666
120. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Recover Study Group et al (2011a) Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26:90-99
121. Trenkwalder C, Kohnen R, Högl B, Metta V, Sixel-Döring F, Frauscher B et al (2011b) Parkinson disease sleep scale - validation of the revised version PDSS-2. Mov Disord 26:644-652
122. Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM (2003) Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. J Neurochem 87:1284-1295
123. Verhagen Metman L, Locatelli ER, Bravi D, Mouradian MM, Chase TN (1997) Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 48:369-372
124. Visser M, Leentjens AF, Marinus J, Stiggelbout AM, van Hilten JJ (2006) Reliability and validity of the Beck depression inventory in patients with Parkinson's disease. Mov Disord 21:668-672
125. Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, 228 Study Investigators et al (2010) Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord 25:858-866
126. Weintraub D, Nirenberg MJ (2013) Impulse control and related disorders in Parkinson's disease. Neurodegener Dis 11:63-71
127. Wilding IR, Hardy JG, Davis SS, Melia CD, Evans DF, Short AH et al (1991) Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR). Clin Neuropharmacol 14:305-321
128. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J et al (2002) Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59:408-413
129. Witjas T, Kaphan E, Azulay JP (2007) Non-motor fluctuations in Parkinson's disease. Rev Neurol (Paris) 163:846-850
130. Youdim MB, Bakhle YS (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147(Suppl 1):S287-S296
131. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46
132. Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, Quality Standards Subcommittee of the American Academy of Neurology et al (2010) Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74:924-931